Thromboelastographic study of thrombosis in the implantable central venous access device

Y R Wen, W Y Ho, W. Z. Sun, C H Or, M. Y. Yeh, Chen Wen Yao, Yu-Ting Tai

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND: In the present study thromboelastography (TEG) was to study whether or not hypercoagulopathy might contribute to the thrombosis of implantable central venous access device (Port-A-Cath, Pharmacia) in cancer patients.

METHODS: All 76 oncological patients who were enrolled in this study had their R time, alpha angle and MA value measured before Port-A-Cath implantation, of whom 11 patients received re-implantation because of thrombotic device. We compared the measurements of these 11 patients (thrombotic group) with that of 65 patients (control group) who received Port-A-Cath implantation for the first time. According to TEG values the hemostatic status in these patients was classified as hypercoagulable, normal or hypocoagulable for comparison. All patients in the control group were followed up for 3 months for occurrence of thrombosis.

RESULTS: It was found that no patient in the thrombotic group was associated with hypercoagulopathy. Five patients (7.5%) in the control group was found in hypercoagulable status at the time of catheter insertion but none of them developed clinical thrombosis during three months of observation. There was no significant difference between the two groups for R time, alpha angle but a higher MA value was found in the control group (p < 0.05). Furthermore, the hypercoagulability (7.5% for the control vs. none for the thrombotic group), hypocoagulability (1.5% vs. 9.1%) and normocoagulability (91.0% vs. 90.9%) were not statistically different between the two groups (Fisher exact test, P = 0.229).

CONCLUSIONS: We conclude that hypercoagulopathy in cancer patients has little, if any, contribution in thrombosis of the implantable central venous access device.

Original languageEnglish
Pages (from-to)223-8
Number of pages6
JournalActa Anaesthesiologica Taiwanica
Volume35
Issue number4
Publication statusPublished - Dec 1997

Fingerprint

Thrombosis
Equipment and Supplies
Vascular Access Devices
Thrombelastography
Control Groups
Thrombophilia
Hemostatics
Neoplasms
Catheters
Observation

Keywords

  • Adult
  • Aged
  • Catheterization, Central Venous
  • Catheters, Indwelling
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms
  • Thrombelastography
  • Thrombosis
  • Journal Article

Cite this

Wen, Y. R., Ho, W. Y., Sun, W. Z., Or, C. H., Yeh, M. Y., Yao, C. W., & Tai, Y-T. (1997). Thromboelastographic study of thrombosis in the implantable central venous access device. Acta Anaesthesiologica Taiwanica, 35(4), 223-8.

Thromboelastographic study of thrombosis in the implantable central venous access device. / Wen, Y R; Ho, W Y; Sun, W. Z.; Or, C H; Yeh, M. Y.; Yao, Chen Wen; Tai, Yu-Ting.

In: Acta Anaesthesiologica Taiwanica, Vol. 35, No. 4, 12.1997, p. 223-8.

Research output: Contribution to journalArticle

Wen, YR, Ho, WY, Sun, WZ, Or, CH, Yeh, MY, Yao, CW & Tai, Y-T 1997, 'Thromboelastographic study of thrombosis in the implantable central venous access device', Acta Anaesthesiologica Taiwanica, vol. 35, no. 4, pp. 223-8.
Wen, Y R ; Ho, W Y ; Sun, W. Z. ; Or, C H ; Yeh, M. Y. ; Yao, Chen Wen ; Tai, Yu-Ting. / Thromboelastographic study of thrombosis in the implantable central venous access device. In: Acta Anaesthesiologica Taiwanica. 1997 ; Vol. 35, No. 4. pp. 223-8.
@article{64e845be8cee430986f0281d273ea7ef,
title = "Thromboelastographic study of thrombosis in the implantable central venous access device",
abstract = "BACKGROUND: In the present study thromboelastography (TEG) was to study whether or not hypercoagulopathy might contribute to the thrombosis of implantable central venous access device (Port-A-Cath, Pharmacia) in cancer patients.METHODS: All 76 oncological patients who were enrolled in this study had their R time, alpha angle and MA value measured before Port-A-Cath implantation, of whom 11 patients received re-implantation because of thrombotic device. We compared the measurements of these 11 patients (thrombotic group) with that of 65 patients (control group) who received Port-A-Cath implantation for the first time. According to TEG values the hemostatic status in these patients was classified as hypercoagulable, normal or hypocoagulable for comparison. All patients in the control group were followed up for 3 months for occurrence of thrombosis.RESULTS: It was found that no patient in the thrombotic group was associated with hypercoagulopathy. Five patients (7.5{\%}) in the control group was found in hypercoagulable status at the time of catheter insertion but none of them developed clinical thrombosis during three months of observation. There was no significant difference between the two groups for R time, alpha angle but a higher MA value was found in the control group (p < 0.05). Furthermore, the hypercoagulability (7.5{\%} for the control vs. none for the thrombotic group), hypocoagulability (1.5{\%} vs. 9.1{\%}) and normocoagulability (91.0{\%} vs. 90.9{\%}) were not statistically different between the two groups (Fisher exact test, P = 0.229).CONCLUSIONS: We conclude that hypercoagulopathy in cancer patients has little, if any, contribution in thrombosis of the implantable central venous access device.",
keywords = "Adult, Aged, Catheterization, Central Venous, Catheters, Indwelling, Female, Humans, Male, Middle Aged, Neoplasms, Thrombelastography, Thrombosis, Journal Article",
author = "Wen, {Y R} and Ho, {W Y} and Sun, {W. Z.} and Or, {C H} and Yeh, {M. Y.} and Yao, {Chen Wen} and Yu-Ting Tai",
year = "1997",
month = "12",
language = "English",
volume = "35",
pages = "223--8",
journal = "Asian Journal of Anesthesiology",
issn = "2468-824X",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - Thromboelastographic study of thrombosis in the implantable central venous access device

AU - Wen, Y R

AU - Ho, W Y

AU - Sun, W. Z.

AU - Or, C H

AU - Yeh, M. Y.

AU - Yao, Chen Wen

AU - Tai, Yu-Ting

PY - 1997/12

Y1 - 1997/12

N2 - BACKGROUND: In the present study thromboelastography (TEG) was to study whether or not hypercoagulopathy might contribute to the thrombosis of implantable central venous access device (Port-A-Cath, Pharmacia) in cancer patients.METHODS: All 76 oncological patients who were enrolled in this study had their R time, alpha angle and MA value measured before Port-A-Cath implantation, of whom 11 patients received re-implantation because of thrombotic device. We compared the measurements of these 11 patients (thrombotic group) with that of 65 patients (control group) who received Port-A-Cath implantation for the first time. According to TEG values the hemostatic status in these patients was classified as hypercoagulable, normal or hypocoagulable for comparison. All patients in the control group were followed up for 3 months for occurrence of thrombosis.RESULTS: It was found that no patient in the thrombotic group was associated with hypercoagulopathy. Five patients (7.5%) in the control group was found in hypercoagulable status at the time of catheter insertion but none of them developed clinical thrombosis during three months of observation. There was no significant difference between the two groups for R time, alpha angle but a higher MA value was found in the control group (p < 0.05). Furthermore, the hypercoagulability (7.5% for the control vs. none for the thrombotic group), hypocoagulability (1.5% vs. 9.1%) and normocoagulability (91.0% vs. 90.9%) were not statistically different between the two groups (Fisher exact test, P = 0.229).CONCLUSIONS: We conclude that hypercoagulopathy in cancer patients has little, if any, contribution in thrombosis of the implantable central venous access device.

AB - BACKGROUND: In the present study thromboelastography (TEG) was to study whether or not hypercoagulopathy might contribute to the thrombosis of implantable central venous access device (Port-A-Cath, Pharmacia) in cancer patients.METHODS: All 76 oncological patients who were enrolled in this study had their R time, alpha angle and MA value measured before Port-A-Cath implantation, of whom 11 patients received re-implantation because of thrombotic device. We compared the measurements of these 11 patients (thrombotic group) with that of 65 patients (control group) who received Port-A-Cath implantation for the first time. According to TEG values the hemostatic status in these patients was classified as hypercoagulable, normal or hypocoagulable for comparison. All patients in the control group were followed up for 3 months for occurrence of thrombosis.RESULTS: It was found that no patient in the thrombotic group was associated with hypercoagulopathy. Five patients (7.5%) in the control group was found in hypercoagulable status at the time of catheter insertion but none of them developed clinical thrombosis during three months of observation. There was no significant difference between the two groups for R time, alpha angle but a higher MA value was found in the control group (p < 0.05). Furthermore, the hypercoagulability (7.5% for the control vs. none for the thrombotic group), hypocoagulability (1.5% vs. 9.1%) and normocoagulability (91.0% vs. 90.9%) were not statistically different between the two groups (Fisher exact test, P = 0.229).CONCLUSIONS: We conclude that hypercoagulopathy in cancer patients has little, if any, contribution in thrombosis of the implantable central venous access device.

KW - Adult

KW - Aged

KW - Catheterization, Central Venous

KW - Catheters, Indwelling

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasms

KW - Thrombelastography

KW - Thrombosis

KW - Journal Article

M3 - Article

C2 - 9553238

VL - 35

SP - 223

EP - 228

JO - Asian Journal of Anesthesiology

JF - Asian Journal of Anesthesiology

SN - 2468-824X

IS - 4

ER -